Intellia Therapeutics, Inc. (NTLA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 44%; Below-average business quality.
Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z (Phase 3 HAELO trial for hereditary angioedema, topline data expected mid-2026, BLA planned H2 2026) and nex-z (Phase 3 for ATTR amyloidosis; MAGNITUDE on FDA... Read more
Sell if holding. Engine safety override at $13.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 44%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.6/10, high confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Intellia Therapeutics, Inc.
Latest news
- NEWS Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target — benzinga Jun 15, 2026 positive
- NEWS Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target — benzinga Jun 15, 2026 neutral
- NEWS Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder — benzinga Jun 15, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target — benzinga Jun 15, 2026 positive
- NEWS Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAEL — benzinga Jun 15, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -9.5% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 44%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $12.89. Score 3.6/10, high confidence.
Take-profit target: $23.97 (+72.9% upside). Prior stop was $12.89. Stop-loss: $12.89.
Quality below floor (1.8 < 4.0).
Intellia Therapeutics, Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 5.4/10. Verdict: Sell.
28 analysts cover NTLA with a consensus score of 3.6/5. Average price target: $27.
What does Intellia Therapeutics, Inc. do?Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z...
Intellia Therapeutics is a clinical-stage biopharma developing CRISPR gene editing therapies. Lead programs: lonvo-z (Phase 3 HAELO trial for hereditary angioedema, topline data expected mid-2026, BLA planned H2 2026) and nex-z (Phase 3 for ATTR amyloidosis; MAGNITUDE on FDA clinical hold since Oct 2025, MAGNITUDE-2 hold lifted Jan 2026). Regeneron shares ~25% of worldwide ATTR development costs and profits.